Principal Financial Group Inc. Has $2.61 Million Holdings in Spark Therapeutics, Inc. (ONCE)

Principal Financial Group Inc. boosted its stake in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 12.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,689 shares of the biotechnology company’s stock after buying an additional 4,937 shares during the period. Principal Financial Group Inc. owned 0.14% of Spark Therapeutics worth $2,610,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. BNP Paribas Arbitrage SA lifted its holdings in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the period. Highbridge Capital Management LLC purchased a new stake in Spark Therapeutics during the first quarter worth $227,000. KCG Holdings Inc. lifted its holdings in Spark Therapeutics by 9.4% during the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after buying an additional 538 shares during the period. Legal & General Group Plc lifted its holdings in Spark Therapeutics by 16.8% during the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after buying an additional 1,286 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. purchased a new stake in Spark Therapeutics during the first quarter worth $572,000. Institutional investors own 77.84% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Principal Financial Group Inc. Has $2.61 Million Holdings in Spark Therapeutics, Inc. (ONCE)” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://transcriptdaily.com/2017/10/08/principal-financial-group-inc-has-2-61-million-holdings-in-spark-therapeutics-inc-once.html.

A number of analysts have weighed in on the company. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $111.00 target price on shares of Spark Therapeutics in a report on Friday. SunTrust Banks, Inc. restated a “buy” rating and set a $95.00 target price (up previously from $85.00) on shares of Spark Therapeutics in a report on Monday, September 25th. Barclays PLC assumed coverage on Spark Therapeutics in a report on Wednesday, September 6th. They set an “overweight” rating and a $104.00 target price for the company. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a report on Friday, August 25th. Finally, Royal Bank Of Canada assumed coverage on Spark Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $100.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $88.38.

Shares of Spark Therapeutics, Inc. (ONCE) opened at 87.44 on Friday. Spark Therapeutics, Inc. has a 12 month low of $35.07 and a 12 month high of $91.00. The firm’s market capitalization is $2.73 billion. The firm’s 50-day moving average price is $85.86 and its 200 day moving average price is $85.86.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same period in the previous year, the company posted ($1.04) earnings per share. Spark Therapeutics’s quarterly revenue was up 14.7% on a year-over-year basis. Analysts anticipate that Spark Therapeutics, Inc. will post ($7.65) earnings per share for the current fiscal year.

In other news, insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $72.53, for a total value of $725,300.00. Following the completion of the sale, the insider now directly owns 220,000 shares of the company’s stock, valued at $15,956,600. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at $18,524,400. The disclosure for this sale can be found here. Insiders sold 1,333,195 shares of company stock valued at $109,070,506 over the last ninety days. Corporate insiders own 7.30% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply